Johnson & Johnson (NYSE:JNJ) Trading Up 0% – Here’s Why

Johnson & Johnson (NYSE:JNJ)’s stock price traded up 0% during mid-day trading on Wednesday . The company traded as high as $164.45 and last traded at $163.51. 1,096,675 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 6,989,499 shares. The stock had previously closed at $163.45.

Analysts Set New Price Targets

JNJ has been the subject of several research reports. TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Stock Performance

The firm has a market capitalization of $387.19 billion, a PE ratio of 10.14, a PEG ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $163.38 and a 200 day moving average of $154.98.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter last year, the company posted $2.66 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds have recently made changes to their positions in the business. Constitution Capital LLC lifted its position in Johnson & Johnson by 2.0% during the first quarter. Constitution Capital LLC now owns 15,677 shares of the company’s stock valued at $2,480,000 after buying an additional 300 shares during the period. RMR Wealth Builders raised its stake in Johnson & Johnson by 20.8% during the first quarter. RMR Wealth Builders now owns 5,394 shares of the company’s stock valued at $853,000 after buying an additional 928 shares during the last quarter. Brookstone Capital Management grew its stake in shares of Johnson & Johnson by 24.9% in the first quarter. Brookstone Capital Management now owns 86,516 shares of the company’s stock worth $13,686,000 after acquiring an additional 17,237 shares during the last quarter. AHL Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 5.0% during the first quarter. AHL Investment Management Inc. now owns 17,322 shares of the company’s stock valued at $2,740,000 after acquiring an additional 828 shares in the last quarter. Finally, Future Financial Wealth Managment LLC increased its stake in Johnson & Johnson by 4.6% during the 1st quarter. Future Financial Wealth Managment LLC now owns 3,612 shares of the company’s stock valued at $571,000 after purchasing an additional 160 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.